Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05079126 · ClinicalTrials.gov registry record · Phase 2
Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease
A Phase 2 study, sponsored by Diffusion Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT05079126 is a Phase 2 study that was terminated before completion, run by Diffusion Pharmaceuticals. The registered enrollment target is 18 participants.
The verdict
NCT05079126, a Phase 2 study, was terminated before completion, sponsored by Diffusion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a randomized, placebo-controlled study of Trans Sodium Crocetinate (TSC) in patients with Interstitial Lung Disease (ILD), age 30-85 (inclusive). The primary objective of the study is to determine the effect of TSC on lung function as measured by diffusing capacity of the lungs for carbon monoxide (DLCO) in patients with ILD; the secondary objectives are to determine the effect of TSC on the 6-minute walk test (6MWT), heart rate recovery (HRR), and Borg Scale in patients with ILD.
Interventions
- DRUG Placebo
- DRUG Trans Sodium Crocetinate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-12-02 |
| Est. Completion | 2022-05-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05079126
The ClinicalTrials.gov registry entry for NCT05079126 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Diffusion Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05079126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05079126 about?
NCT05079126 is a clinical study titled "Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease". This is a randomized, placebo-controlled study of Trans Sodium Crocetinate (TSC) in patients with Interstitial Lung Disease (ILD), age 30-85 (inclusive). The primary objective of the study is to determine the effect of TSC on lung function as measured by diffusing capacity of the lungs for carbon mo...
What is the current status of trial NCT05079126?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2021-12-02. Estimated completion is 2022-05-27.
What interventions are being tested in trial NCT05079126?
The interventions under investigation include: Placebo (DRUG), Trans Sodium Crocetinate (DRUG).
Who is sponsoring clinical trial NCT05079126?
This trial is sponsored by Diffusion Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.